Cannabis Science Inc (OTCMKTS:CBIS) has joined forces with IBX Bio Inc. for an FDA accepted clinical trial. The trial will research the use of the combination of CS-TATI-1 and GenePro®.
The details
CS-TATI-1 is a cannabinoid based drug whereas GenePro® is the lead product of the biotechnology firm IBX Bio Inc. The later firm has formulated DNA constructs of non-infectious HIV which they believe will result antibodies. The collaboration between the two firms is historic, increasing the synergistic effects of advanced HIV immunotherapy and cannabinoids.
The extensive research highlights that effects of CBDs reduces inflammation and also blocks HIV replication. Both the things are correlated with each other as HIV causes inflammation, even when it is at low levels. Cannabis Science believes CBDs are the ‘missing puzzle piece’ to complete picture of GenePro®.
The expert comments
Mr. Raymond C. Dabne, the President of Cannabis Science states that the alliance with IGX Bio is planned to help offer new insights into the function of inflammation and healing vaccination of HIV as a vital step for getting effective treatments for AIDS patients in different resource settings.
These trials will offer a scientific evaluation of CS-TATI-1 and GenePro® to show the increased potential of the anti-inflammatory effects of CBDs and therapeutic vaccination to deter disease growth in AID patients unable to reach control HIV replication. The company is currently focusing on lead drug CS-TATI-1 along with two other drugs.
The expectations
IBX states only GenePro® stimulates an antibody as well as a cellular response in HIV patients. The drug CS-TATI-1 is not planned to buffer the impact of the drug, but it is aimed to systematically destruct HIV copies concurrently with GenePro®. The plan is to slow down HIV without harsh side effects.
